Research Hub

The supplied search results do not contain 4-5 peer-reviewed supplement studies from the last 30 days. The most recent directly relevant item is a 2026 NIH/PubMed report on rising U.S. supplement use, but it is not a clinical efficacy finding.

Nature Portfolio’s supplement research page highlights a preclinical/clinical signal that nicotinamide may help restore NAD+ in heart failure with preserved ejection fraction, and notes potassium-enriched salt reduced stroke and cardiovascular events in SSaSS.

A nationwide cohort study found no association between ever using dietary supplements and mortality outcomes. Benefits from adequate vitamin A, vitamin K, magnesium, and zinc intake were confined to foods, not supplements.

NIH-funded analysis reported that dietary supplement use was not associated with lower death risk overall, while adequate intake of some nutrients was beneficial when obtained from food rather than supplements.

A nationally representative trend analysis found overall dietary supplement use increased from 51.8% in 2011-2012 to 61.4% in 2021-2023, with larger use of multiple products and specific supplements like vitamin D, zinc, and probiotics.

The REDUCE-IT trial found that 4 g/day of highly purified EPA ethyl ester added to statin therapy cut major cardiovascular events by about 25% in patients with high triglycerides and cardiovascular disease or diabetes.

A global overview reported increased use of vitamin C, vitamin D, zinc, omega-3s, probiotics, and selenium during the COVID-19 pandemic, mainly for perceived immune support and infection risk reduction.

An analysis of 63,442 adults showed declining multivitamin/multimineral use over 25 years while targeted supplements for immunity, gut, skin, and joint health have increased, especially since around 2010.

A large NHANES analysis found US adult supplement use rose from 51.8% to 61.4% between 2011–2012 and 2021–2023, with more people using multiple products and sharp growth in vitamin D, zinc, probiotics, fiber, and ginger.

New data identify a niacin-derived metabolite that promotes vascular inflammation in preclinical models and is associated with increased major adverse cardiovascular events in humans, suggesting high-dose niacin supplements may raise CVD risk.

Recent research links NAD+ deficiency to heart failure with preserved ejection fraction and suggests that restoring NAD+ levels with nicotinamide supplementation may improve diastolic function.

NHANES analysis shows US adult supplement use increased from 51.8% to 61.4% between 2011–2012 and 2021–2023, with notable growth in use of vitamin D, zinc, probiotics, fiber, and other targeted products.

A study of 63,442 US adults over 25 years finds declining multivitamin use and rising uptake of specialized supplements marketed for immunity, gut, skin, and joint health, especially among older adults.

Analysis of NHANES 2007–2018 data found that 53% of the US population aged ≥1 year used at least one dietary supplement daily, predominantly micronutrient products, with higher use in women, older adults, and non-Hispanic whites.[6]

A JAMA Network Open analysis of 63,442 US adults from 1999–2023 shows overall supplement use rose to 60%, with use shifting away from multivitamins toward targeted products for immunity, inflammation, gut, skin, and joint health, especially in older adults.[5]

Within non-multivitamin supplements, vitamin D and zinc had the greatest rise in use among US adults, with additional increases in vitamin K, biotin, B12, magnesium, and other minerals, particularly after 2009–2014.[5]

The US Preventive Services Task Force concluded there is inadequate evidence that commonly used vitamin, mineral, and multivitamin supplements prevent heart disease, stroke, or cancer, and specifically advises against beta-carotene due to increased lung cancer risk in smokers and asbestos-exposed workers.[7]

A global overview of dietary supplements reports marked increases in use of vitamins C and D and zinc during the COVID-19 pandemic, as these were among the most commonly chosen products to boost immunity and reduce perceived infection risk.[4]

A JAMA Network Open analysis of 63,442 US adults (1999–2023) found overall supplement use rose to 61.4%, with multivitamin use declining and growth in targeted products like fiber, probiotics, and immunity/gut health supplements.[5]

A global regulatory review reports increased use of vitamin C, vitamin D, zinc, omega-3s, probiotics, and selenium during the COVID-19 pandemic, mainly to boost immunity and reduce perceived infection risk.[4]

An updated USPSTF recommendation states there is inadequate evidence that common vitamin, mineral, or multivitamin supplements prevent cardiovascular disease, stroke, or cancer, and specifically advises against beta-carotene due to increased lung cancer risk in smokers.[8]

A recent research news report highlights that US adults increasingly choose niche supplements for immunity, inflammation, gut, skin, and joint health, while multivitamin use has fallen, especially among younger and middle-aged adults.[6]

A Nature Portfolio report says excess niacin produces a metabolite that promotes vascular inflammation in preclinical models and is associated with higher major adverse cardiovascular event rates in humans.

Analysis of 63,442 US adults shows supplement use rose from 51% to 60% between 1999–2000 and 2021–2023, with use shifting away from multivitamin–multimineral products toward targeted vitamins, minerals, and botanicals for immunity, gut, joint, skin, and inflammation.[4]

Recent NHANES analysis showed that about two-thirds of US adults who use supplements take at least one product on 24 or more days in a 30‑day period, indicating high day‑to‑day adherence that may increase cumulative exposure and potential benefits or risks.[2]

A methodological paper in Frontiers in Nutrition outlines best practices for supplement trials, emphasizing the need for strong preclinical safety and efficacy data, clear endpoints, and robust randomized designs before claiming health benefits from vitamins, minerals, botanicals, or nootropics.[4]

The REDUCE-IT randomized trial found that high-dose purified EPA (icosapent ethyl, 4 g/day) added to statin therapy reduced major cardiovascular events by about 25% in high‑risk patients with elevated triglycerides, supporting targeted omega‑3 use rather than general multivitamin use.[3]

A large NHANES-based study of 63,442 US adults found overall supplement use rose from 51% to 60% between 1999–2000 and 2021–2023, with use shifting away from multivitamin–multimineral products toward targeted vitamin D, zinc, and immune/gut/joint health supplements, especially in older adults.[5]

In U.S. adverse event reports, weight loss, muscle building, and energy supplements were linked to nearly three times the risk of severe medical outcomes (including death and hospitalization) in children and young adults compared with vitamins, highlighting substantial safety concerns for non‑vitamin products marketed for performance.

High-dose cholecalciferol (≥280,000 IU over 7 weeks) in hospitalized COVID-19 patients was associated with reduced mortality risk, suggesting potential benefit of vitamin D supplementation for severe respiratory infection outcomes, though effects on length of stay were not observed.

Administration of 12 g intravenous vitamin C every 12 hours for 7 days in 56 critically ill COVID-19 patients showed a promising reduction in 28‑day mortality, indicating potential clinical utility of short‑term high‑dose vitamin C in severe illness, pending larger trials.

A combination of vitamins C and E, zinc, copper, lutein, and zeaxanthin (AREDS formula) has been shown to slow further vision loss in people with age-related macular degeneration, supporting targeted antioxidant and mineral supplementation for high‑risk eye health.

Recent randomized trials and meta-analyses indicate that omega‑3 supplementation yields modest reductions in major vascular events and coronary heart disease outcomes, though a large trial using 4 g EPA+DHA in high‑risk patients showed no benefit, underscoring that cardiovascular gains depend on dose and formulation.

An updated meta-analysis of randomized trials found that regular daily or weekly vitamin D supplementation produced a modest reduction in acute respiratory infections, with greatest benefit in people who were initially deficient.

A clinical trial in critically ill COVID-19 patients given high-dose intravenous vitamin C reported a promising reduction in 28-day mortality, though effects on length of stay and other outcomes were inconclusive.

Analysis of adverse event reports in young people found weight loss, muscle-building, and energy supplements were linked to nearly three times more severe medical events, including hospitalization and death, compared to vitamins.

In a cohort of hospitalized COVID-19 patients, very high-dose cholecalciferol over several weeks was associated with reduced mortality regardless of baseline vitamin D status, with no clear change in hospital stay length.

The REDUCE-IT randomized trial showed that 4 g/day of highly purified EPA ethyl ester significantly lowered major cardiovascular events in statin-treated patients with elevated triglycerides compared with placebo.